Secreted phospholipase A2 type IIA as a mediator connecting innate and adaptive immunity: New role in atherosclerosis

Cardiovascular Research

Volumn 81, Issue 1, 2009, Pages 54-63

  Ibeas, Elvira ^a   Fuentes, Lucía ^a   Martín, Rubén ^a   Hernández, Marita ^a   Nieto, Maria Luisa ^a  

^a UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Atherosclerosis; Dendritic cells; Inflammation; Macrophages; sPLA 2 IIA

Indexed keywords

CD14 ANTIGEN; CD40 ANTIGEN; CD61 ANTIGEN; CD83 ANTIGEN; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERCELLULAR ADHESION MOLECULE 3; L SELECTIN; PHOSPHOLIPASE A2 GROUP II; PHOSPHOLIPASE A2 GROUP IIA; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; ICAM3 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL ADHESION; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CELL SURFACE; DENDRITIC CELL; ENZYME RELEASE; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; MONONUCLEAR CELL; MORPHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; ACTIVE IMMUNIZATION; ANIMAL; CHEMOTAXIS; DOSE RESPONSE; ENDOCYTOSIS; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD14; ATHEROSCLEROSIS; CELL ADHESION MOLECULES; CELL DIFFERENTIATION; CELL LINE; CHEMOTAXIS; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCYTOSIS; GROUP II PHOSPHOLIPASES A2; HUMANS; IMMUNITY, ACTIVE; IMMUNITY, INNATE; MICE; MONOCYTES; TRANSFECTION;

EID: 57749195888     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn234     Document Type: Article

References (38)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-126.
2. Wick G, Schett G, Amberger A, Kleindeinst R, Xu Q. Is atherosclerosis an immunologically mediated disease? Immuno Today 1995;16:27-33.
3. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002;91:281-291.
4. Nicoletti A, Caligiuri G, Hansson GK. Immunomodulation of atherosclerosis: myth and reality. J Intern Med 2000;247:397-405.
5. Link A, Bohm M. Potential role of dendritic cells in atherosclerosis. Cardiovasc Res 2002;55:708-709.
6. Lord RS, Bobryshev YV. Clustering of dendritic cells in athero-prone areas of the aorta. Atherosclerosis 1999;146:197-198.
7. Millong G, Malcom GT, Wick G. Early inflammatory-immunological lesions in juvenile atherosclerosis from The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Atherosclerosis 2002;160:441-448.
8. Millonig G, Niederegger H, Rabl W, Hochleitner BW, Hoefer D, Romani N et al. Network of vascular-associated dendritic cells in intima of healthy young individuals. Arterioscler Thromb Vasc Biol 2001;21:503-508.
9. Ozem J, Bobryshev YV, Lord RS, Ashwell KW. Identification of dendritic cells in aortic atherosclerosic lesions in rats with diet-induced hypercholesteraemia. Histol Histopathol 2002;17:223-237.
10. Soilleux EJ, Morris LS, Trowsdale J, Coleman N, Boyle JJ. Human atherosclerotic plaques express DC-SIGN, a novel protein found on dendritic cells and macrophages. J Pathol 2002;198:511-516.
11. Macatonia SE, Hosken NA, Litton M, Vieira P, Hsieh CS, Culpepper JA et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 1995;154:5071-5079.
12. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003;21:685-711.
13. Heath WR, Belz GT, Behrens GM, Smith CM, Forehan SP, Parish IA et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev 2004;199:9-26.
14. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
15. 2. Blood 2005;105:3583-3587.
16. 2 enzymes: classification and characterization. Biochim Biophys Acta 2000;1488:1-19.
17. 2 in patients with coronary artery disease undergoing percutaneous coronary intervention. Eur Heart J 2003;24:1824-1832.
18. 2. Biochim Biophys Acta 2000;1488:149-158.
19. 2 in human atherosclerotic plaques. Atherosclerosis 1995;118:173-181.
20. 2 in normal and atherosclerotic arteries: activity of the isolated enzyme on low density lipoproteins. Arterioscler Thromb Vasc Biol 1997;17:300-309.
21. 2 induces particle fusion and enhances the retention of LDL to human aortic proteoglycans. Arterioscler Thromb Vasc Biol 2001;21:1053-1058.
22. 2 in nerve growth factor-stimulated rat serosal mast cells is facilitated by interaction with fibroblasts and mediated by a mechanism independent of their enzymatic functions. J Immunol 1998;161:5008-5015.
23. 2 elicits proinflammatory changes and upregulates the surface expression of Fas ligand in monocytic cells: potential relevance for atherogenesis. Circ Res 2002;90:38-45.
24. 2 gene in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2005;25:1161-1167.
25. Puig-Kröger A, Serrano-Gómez D, Caparrós E, Domínguez-Soto A, Relloso M, Colmenares M et al. Regulated expression of the pathogen receptor dendritic cell-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin in THP-1 human leukemic cells, monocytes, and macrophages. J Biol Chem 2004;279:25680-25688.
26. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001;106:255-258.
27. Roake JA, Rao AS, Morris PJ, Larsen CP, Hankins DF, Austyn JM. Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1. J Exp Med 1995;181:2237-2247.
28. Alderman CJ, Bunyard PR, Chain BM, Foreman JC, Leake DS, Katz DR. Effects of oxidized low density lipoprotein on dendritic cells: a possible immunoregulatory component of the atherogenic microenvironment? Cardiovascular Res 2002;55:806-819.
29. Aicher AH, Heeschen C, Mohaupt M, Cooke JP, Zeiher AM, Dimmeler S. Nicotine strongly activates DC-mediated adaptive immunity: potential role for progression of atherosclerotic lesions. Circulation 2003;107:604- 611.
30. + monocyte-derived dendritic cell differentiation, maturation and function. Eur J Immunol 2006;36:2993-3006.
31. 2 induces dendritic cell maturation. Eur J Immunol 2004;34:2293-2302.
32. Coutant F, Agaugué S, Perrin-Cocon L, André P, Lotteau V. Sensing environmental lipids by dendritic cell modulates its function. J Immunol 2004;172:54-60.
33. Coutant F, Perrin-Cocon L, Agaugue S, Delair T, Andre P, Lotteau V. Mature dendritic cell generation promoted by lysophosphatidylcholine. J Immunol 2002;169:1688-1695.
34. Xia C-Q, Peng R, Beato F, Clare-Salzler MJ. Dexamethasone induces IL-10-producing monocyte-derived dendritic cells with durable immaturity. Scandinavian J Immunol 2005;62:45-54.
35. Delneste Y, Charbonnier P, Herbault N, Magistrelli G, Caron G, Bonnefoy J-Y et al. Interferon-gamma switches monocyte differentiation from dendritic cells to macrophages. Blood 2003;101:143-150.
36. Chomarat P, Dantin C, Bennett L, Banchereau J, Palucka AK. TNF skews monocyte differentiation from macrophages to dendritic cells. J Immunol 2003;171:2262-2269.
37. Giordano D, Magaletti DM, Clark EA, Beavo JA. Cyclic nucleotides promote monocyte differentiation toward a DC-SIGN+ (CD209) intermediate cell and impair differentiation into dendritic cells. J Immunol 2003;171:6421- 6430.
38. Cho HJ, Shashkin P, Gleissner CA, Dunson D, Jain N, Lee JK et al. Induction of dendritic cell-like phenotype in macrophages during foam cell formation. Physiol Genomics 2007;29:149-116.